MAOB and Alzheimer disease: Reversible inhibition of MAO-B, a flavin adenine dinucleotide(FAD)-dependentenzyme, located in glial cells and mainly expressed in the corticaland hippocampal regions of the brain, has recently been considereda valuable therapeutic approach for AD.15 Preclinical studies demonstrated that reversible MAO-B inhibitors,as opposed to irreversible ones, can ameliorate cognitive deficitsin transgenic mice with APP/PS1 mutations following a 4 week treatment.16 This positive effect could be explained by thecontribution of MAO-B to GABA-ergic transmission.